Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.

Antiviral research - 1 Sept 2015

Genebat Miguel, de Pablo-Bernal Rebeca S, Pulido Ildefonso, Jiménez-Mejías Manuel E, Martínez Onofre, Pacheco Yolanda M, Raffi-El-Idrissi Benhia Mohammed, Abad María Antonia, Ruiz-Mateos Ezequiel, Leal Manuel

Abstract excerpt

Our aim was to analyze the virological response to a combined antiretroviral therapy started after Maraviroc Clinical Test (MCT) in naïve HIV-infected patients. Forty-one patients were exposed to MCT, based on an 8-day MVC monotherapy. If undetectability or a viral load reduction >1 log10 HIV-RNA copies/ml was achieved, a MVC-containing cART was prescribed. Forty patients showed a positive MCT; undetectability...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cyclohexanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotyping Techniques

Share to HIV Infections

Share to Triazoles

Share to Viral Load

Share to Viral Tropism

Source

Identifiers

PMID: 26122170
DOI: 10.1016/j.antiviral.2015.06.018

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.PMID 26122170Read ↗

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Semantic proximity Read ↗

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.Semantic proximity Read ↗

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.Semantic proximity Read ↗

Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.Semantic proximity Read ↗

[Methods for determination of HIV tropism and their clinical use].Semantic proximity Read ↗

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.Semantic proximity Read ↗

TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic ApproachesSemantic proximity Read ↗

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.Semantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.Semantic proximity Read ↗

Determination of HIV tropism and its use in the clinical practice.Semantic proximity Read ↗

HIV population genotypic tropism testing and its clinical significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.